You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
BGI is also developing sequencing-based self-sampling assays for pharmacogenomics and hereditary cancer testing.
The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.
The new agreement between the two companies commits to expanding the clinical genetic testing market in Turkey and is part of a global expansion for BGI.
The new institute, co-located with the China National GeneBank, will focus on synthetic biology technologies and applications.
Researchers found microbial communities at sites of the female reproductive tract thought to be sterile, and linked certain microbes to disease states.
People with atherosclerotic cardiovascular disease have increased levels of certain bacteria in their stool, a metagenome-wide association study has found.
Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
The company's Hong Kong laboratory was established in 2010 and was accredited by the College of American Pathologists in 2013.
A Complete Genomics-led team isolated and sequenced the genomes of 34 circulating tumor cells from a woman with metastatic breast cancer.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.